Abstract FKBP12, a peptidyl‐prolyl isomerase implicated in cancer, neurodegenerative diseases, and post‐transplant anti‐rejection mechanisms, represents a critical biomarker for early diagnosis and monitoring. Here, a novel diagnostic nanoplatform is presented for the detection of FKBP12 at nanomolar to picomolar concentrations in biological fluids. The platform integrates a gold‐coated Quartz Crystal Microbalance (QCM) functionalized with a synthetic receptor (GPS‐SH1) and spacers within a Self‐Assembled Monolayer (SAM), enabling direct and label‐free detection of FKBP12 in complex biological samples. A careful strategy for the in‐silico design and custom synthesis of the receptor is adopted, ensuring optimal binding affinity and additional chemical functionalities for surface chemisorption. The designed nano‐architecture demonstrates exceptional sensitivity, with a detection limit in the picomolar range, and high selectivity, as confirmed by minimal interference from abundant serum proteins such as Serum Albumin and Immune Gamma Globulin. Furthermore, the SAM‐functionalized sensors exhibit remarkable stability, retaining functionality for up to six months under storage conditions. This work not only advances the field of nanoscale biosensing but also provides a robust, reusable tool for FKBP12 detection, with potential applications in point‐of‐care diagnostics and personalized medicine. The platform's ability to operate in biologically relevant environments underscores its promise for real‐world healthcare applications, including early disease diagnostics.
Tozzetti et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: